230 likes | 373 Views
ICAP-supported HIV care and treatment services in Rwanda. Number of ICAP-supported facilities by USG-funded activity, Rwanda. Source: ICAP Rwanda Site Census, August 2007. Cumulative enrollment in HIV care (pre-ART and ART) & ART care at ICAP-supported facilities, July 2004 – June 2007.
E N D
Number of ICAP-supported facilities by USG-funded activity, Rwanda Source: ICAP Rwanda Site Census, August 2007
Cumulative enrollment in HIV care (pre-ART and ART) & ART care at ICAP-supported facilities, July 2004 – June 2007 HIV care (pre-ART & ART) ART care ART patients retained* Source: ICAP URS, July 2007 *Includes ART patients who are not known to have died, transferred or lost to follow-up.
Cumulative pediatric enrollment in HIV care (pre-ART and ART) & ART care at ICAP-supported facilities, July 2004 – June 2007 HIV care (pre-ART & ART) ART care ART patients retained* Source: ICAP URS, July 2007 *Includes ART patients who are not known to have died, transferred or lost to follow-up.
Number of ICAP-supported care and treatment facilities reporting, July 2004 – June 2007 Source: ICAP URS, July 2007
Pediatric (<15) enrollment in HIV care (% of total patients) at ICAP-supported facilities as of June 2007 Source: ICAP URS, July 2007
Target HIV care enrollment to February 2008 and actual enrollment at ICAP-supported facilities as of June 2007 Source: ICAP Rwanda Site Census, August 2007
Cumulative enrollment in pre-ART and ART care by age and sex at ICAP-supported facilities as of June 2007 (Total in care = 26,827) n=13,794 n=13,033 n=26,827 Source: ICAP URS, July 2007
Cumulative pediatric (<15) enrollment in pre-ART and ART care by age at ICAP-supported facilities, June 2007 (Total in care = 2,842) n=1,566 n=1,276 n=2,842 Source: ICAP URS, July 2007
ART regimens at ICAP-supported facilities by age, April-June 2007 Source: ICAP URS, July 2007
Percentage of patients with CD4 counts at baseline, 6 and 12 months after ART initiation over time at ICAP-supported facilities to June 2007* Number of patients at baseline n=na n=888 n=892 n=1,087 *CD4 data are for a subset of patients Source: ICAP URS, July 2007
Average median CD4 count (cells/µL) after 6 and12 months of ART over time at ICAP-supported sites to June 2007* Number of patients at baseline Number of patients at baseline n=na n=na n=888 n=892 n=1,087 Source: ICAP URS, July 2007 *CD4 data are for a subset of patients initiating ART
Reasons for ART discontinuation at ICAP-supported sites as of June 2007* Unknown <1% <1 per 1,000 person-years LTF13% 8 per 1,000 person-years Dead 76% 46 per 1,000 person-years 7 per 1,000 person-years Stopped ART 11% Source: ICAP URS, July 2007 *Does not include patients who transferred out
Program and Facility Characteristics Tracking System (P-FaCTS)
On-site services at ICAP-supported care and treatment facilities*,Rwanda (n=32 of 35) 1 service 3% 2 services 6% n=25/32 n=28/32 n=29/32 n=30/32 n=28/32 3 services 9% 4 services 13% 5 services 69% Source ICAP Rwanda P-FaCTS, January 2007 *Includes data from 32 of 35 facilities (91%) for which a P-FaCTS assessment has been completed
Patient support services at ICAP-supported care and treatment facilities*,Rwanda (n=32 of 35) 5 services 3% n=32/32 n=4/32 n=6/32 n=7/32 n=28/32 1 service 10% 4 services 6% 3 services 28% 2 services 53% Source ICAP Rwanda P-FaCTS, January 2007 *Includes data from 32 of 35 facilities (91%) for which a P-FaCTS assessment has been completed
Median number of staff per 1000 patients on ART at ICAP-supported care and treatment facilities in Rwanda by cadre* (n=32 of 35) Source ICAP Rwanda P-FaCTS, January 2007 *Includes data from 32 of 35 facilities (91%) for which a P-FaCTS assessment has been completed
Pregnant women counseled and tested in ANC atICAP/CU-supported PMTCT facilities, April-June 2007
HIV-infected pregnant women receiving ART prophylaxis* in ANC at ICAP-supported PMTCT facilities, April-June 2007 *Maternal ART prophylaxis includes: sd-NVP, AZT/sd-NVP, AZT/sd-NVP + 3TC/AZT tail, and HAART at 34 weeks
Women and infants receiving ART prophylaxis* in maternity at ICAP/CU-supported PMTCT facilities, April-June 2007 *Maternal ART prophylaxis includes: sd-NVP, AZT/sd-NVP, AZT/sd-NVP + 3TC/AZT tail, and HAART at 34 weeks
Screening and treatment for active TB among HIV positive persons enrolled in ICAP-supported care and treatment facilities, Rwanda 35 sites 27 sites NA Source: ICAP, URS, January-June 2007 * Sites with missing numerators/denominators were excluded